Tag: 72Week
Complete 72-Week Results from Phase 3 HOPE Study of Oxbryta® (voxelotor)...
SOUTH SAN FRANCISCO, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced The Lancet...